Peter H. Jones, MD

Article

Treating dyslipidemia in the high-risk patient

Author:: Peter H. Jones, MD

Publish date: February 1, 2010

How low should LDL levels be pushed and how important are other lipoproteins in our efforts to reduce CV risk? Here’s an update.

Article

Safety of statins: Effects on muscle and the liver

Author:: Peter H. Jones, MD

Publish date: November 1, 2005

Hepatotoxicity and myopathy are uncommon but worrisome. ALT and AST should be measured at baseline and periodically during statin therapy.

Article

Statins: The case for higher, individualized starting doses

Author:: Peter H. Jones, MD

Publish date: September 1, 2005

We’re not getting our patients’ low-density lipoprotein cholesterol down to goal levels. We would do better by starting at a higher dose if the pat...

Article

Lipid-lowering: Can ezetimibe help close the treatment gap?

Author:: Peter H. Jones, MD

Publish date: September 1, 2003

Ezetimibe (Zetia) is an important new drug for lowering cholesterol and may help overcome some of the barriers.